325 related articles for article (PubMed ID: 29208671)
61. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
[TBL] [Abstract][Full Text] [Related]
62. Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia.
Falk GW; Catalano MF; Sivak MV; Rice TW; Van Dam J
Gastrointest Endosc; 1994; 40(2 Pt 1):207-12. PubMed ID: 8013823
[TBL] [Abstract][Full Text] [Related]
63. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.
Reid BJ; Weinstein WM; Lewin KJ; Haggitt RC; VanDeventer G; DenBesten L; Rubin CE
Gastroenterology; 1988 Jan; 94(1):81-90. PubMed ID: 3335302
[TBL] [Abstract][Full Text] [Related]
64. Barrett's esophagus and Barrett's-related dysplasia.
Goldblum JR
Mod Pathol; 2003 Apr; 16(4):316-24. PubMed ID: 12692197
[TBL] [Abstract][Full Text] [Related]
65. How Should We Report Endoscopic Results in Patient's with Barrett's Esophagus?
Gorrepati VS; Sharma P
Dig Dis Sci; 2018 Aug; 63(8):2115-2121. PubMed ID: 29675664
[TBL] [Abstract][Full Text] [Related]
66. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
67. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
68. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis.
Herszenyi L; Hritz I; Pregun I; Sipos F; Juhasz M; Molnar B; Tulassay Z
World J Gastroenterol; 2007 Feb; 13(5):676-82. PubMed ID: 17278189
[TBL] [Abstract][Full Text] [Related]
69. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
70. Karyometry in Barrett's esophagus.
da Silva VD; Prolla JC; Sharma P; Sampliner R; Thompson D; Bartels PH
Anal Quant Cytol Histol; 2001 Feb; 23(1):40-6. PubMed ID: 11233742
[TBL] [Abstract][Full Text] [Related]
71. From reflux esophagitis to Barrett's esophagus and esophageal adenocarcinoma.
Wang RH
World J Gastroenterol; 2015 May; 21(17):5210-9. PubMed ID: 25954094
[TBL] [Abstract][Full Text] [Related]
72. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
73. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
74. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis.
Böttger TC; Youssef V; Dutkowski P; Maschek H; Brenner W; Junginger T
Cancer; 1998 Sep; 83(6):1074-80. PubMed ID: 9740070
[TBL] [Abstract][Full Text] [Related]
75. Barrett's esophagus, dysplasia, and adenocarcinoma.
Haggitt RC
Hum Pathol; 1994 Oct; 25(10):982-93. PubMed ID: 7927321
[TBL] [Abstract][Full Text] [Related]
76. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
77. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
78. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.
Morita S; Matsumoto Y; Okuyama S; Ono K; Kitamura Y; Tomori A; Oyama T; Amano Y; Kinoshita Y; Chiba T; Marusawa H
Carcinogenesis; 2011 Nov; 32(11):1706-12. PubMed ID: 21890457
[TBL] [Abstract][Full Text] [Related]
79. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.
Raouf AA; Evoy DA; Carton E; Mulligan E; Griffin MM; Reynolds JV
Dis Esophagus; 2003; 16(1):17-23. PubMed ID: 12581249
[TBL] [Abstract][Full Text] [Related]
80. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.
Shirvani VN; Ouatu-Lascar R; Kaur BS; Omary MB; Triadafilopoulos G
Gastroenterology; 2000 Mar; 118(3):487-96. PubMed ID: 10702199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]